CTIC Cti Biopharma Corp

Price (delayed)

$2.19

Market cap

$204.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$174.44M

Sector: Healthcare
Industry: Biotechnology

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their ...

Highlights

Cti Biopharma's debt has shrunk by 60% YoY and by 27% QoQ
The revenue has plunged by 100% YoY
CTIC's gross profit has dropped by 100% year-on-year

Key stats

What are the main financial stats of CTIC
Market
Shares outstanding
93.28M
Market cap
$204.29M
Enterprise value
$174.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$57.12M
EBITDA
-$56.59M
Free cash flow
-$48.56M
Per share
EPS
-$0.77
Free cash flow per share
-$0.64
Book value per share
$0.35
Revenue per share
$0
TBVPS
$0.56
Balance sheet
Total assets
$42.79M
Total liabilities
$16.14M
Debt
$3.25M
Equity
$26.65M
Working capital
$23.79M
Liquidity
Debt to equity
0.12
Current ratio
2.53
Quick ratio
2.39
Net debt/EBITDA
0.53
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-95.7%
Return on equity
-135.1%
Return on invested capital
-2,079.1%
Return on capital employed
-209.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTIC stock price

How has the Cti Biopharma stock price performed over time
Intraday
1.39%
1 week
-2.67%
1 month
-13.44%
1 year
106.6%
YTD
-31.99%
QTD
-24.74%

Financial performance

How have Cti Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$52.91M
Net income
-$57.53M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
CTIC's gross profit has dropped by 100% year-on-year
The net income has decreased by 39% YoY and by 10% QoQ
The operating income has declined by 26% year-on-year and by 11% since the previous quarter

Growth

What is Cti Biopharma's growth rate over time

Valuation

What is Cti Biopharma stock price valuation
P/E
N/A
P/B
6.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 10% year-on-year and by 4.1% since the previous quarter
The price to book (P/B) is 77% higher than the 5-year quarterly average of 3.5 and 29% higher than the last 4 quarters average of 4.8
The company's equity fell by 33% QoQ and by 5% YoY
The revenue has plunged by 100% YoY

Efficiency

How efficient is Cti Biopharma business performance
The company's return on assets fell by 50% YoY and by 30% QoQ
The return on invested capital has declined by 41% since the previous quarter
The ROE has decreased by 11% QoQ

Dividends

What is CTIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTIC.

Financial health

How did Cti Biopharma financials performed over time
CTIC's total assets is 165% greater than its total liabilities
CTIC's quick ratio has plunged by 58% YoY and by 22% from the previous quarter
The current ratio has dropped by 56% year-on-year and by 21% since the previous quarter
Cti Biopharma's debt is 88% lower than its equity
Cti Biopharma's debt has shrunk by 60% YoY and by 27% QoQ
The debt to equity has dropped by 59% year-on-year but it rose by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.